{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:47:37Z","timestamp":1790891257859,"version":"4.1.0"},"reference-count":9,"publisher":"American Diabetes Association","issue":"11","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":3241,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,11,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Remogliflozin etabonate (RE), an inhibitor of the sodium-glucose transporter 2, improves glucose profiles in type 2 diabetes. This study assessed safety, tolerability, pharmacokinetics, and pharmacodynamics of RE in subjects with type 1 diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Ten subjects managed with continuous subcutaneous insulin infusion were enrolled. In addition to basal insulin, subjects received five randomized treatments: placebo, prandial insulin, 50 mg RE, 150 mg RE, and mg RE 500.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Adverse events and incidence of hypoglycemia with RE did not differ from placebo and prandial insulin groups. RE significantly increased urine glucose excretion and reduced the rise in plasma glucose concentration after oral glucose. RE reduced incremental adjusted weighted mean glucose (0\u20134 h) values by 42\u201349 mg\/dL and mean glucose (0\u201310 h) by 52\u201369 mg\/dL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>RE can be safely administered with insulin in type 1 diabetes and reduces plasma glucose concentrations compared with placebo.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc12-0508","type":"journal-article","created":{"date-parts":[[2012,9,27]],"date-time":"2012-09-27T12:55:24Z","timestamp":1348750524000},"page":"2198-2200","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":44,"title":["Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes"],"prefix":"10.2337","volume":"35","author":[{"given":"Sunder","family":"Mudaliar","sequence":"first","affiliation":[{"name":"Medicine Service, Veterans Administration Medical Center, San Diego, California"},{"name":"Department of Medicine, University of California San Diego, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra A.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Medicine Service, Veterans Administration Medical Center, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie A.","family":"Mavian","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Diego, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"O\u2019Connor-Semmes","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research & Development, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia K.","family":"Mydlow","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research & Development, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Ye","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research & Development, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth K.","family":"Hussey","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research & Development, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J.","family":"Nunez","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research & Development, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Henry","sequence":"additional","affiliation":[{"name":"Medicine Service, Veterans Administration Medical Center, San Diego, California"},{"name":"Department of Medicine, University of California San Diego, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Dobbins","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research & Development, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2012,10,13]]},"reference":[{"key":"2022031221150010800_B1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejphar.2009.03.007","article-title":"Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats","volume":"609","author":"Fujimori","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"2022031221150010800_B2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","article-title":"The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose","volume":"93","author":"Kanai","year":"1994","journal-title":"J Clin Invest"},{"key":"2022031221150010800_B3","first-page":"F459","article-title":"Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter","volume":"263","author":"Wells","year":"1992","journal-title":"Am J Physiol"},{"key":"2022031221150010800_B4","doi-asserted-by":"crossref","first-page":"29365","DOI":"10.1074\/jbc.270.49.29365","article-title":"Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney","volume":"270","author":"You","year":"1995","journal-title":"J Biol Chem"},{"key":"2022031221150010800_B5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1463-1326.2011.01462.x","article-title":"Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients","volume":"14","author":"Dobbins","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2022031221150010800_B6","doi-asserted-by":"crossref","DOI":"10.1111\/j.1463-1326.2012.01569.x","article-title":"Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus","author":"Luippold","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2022031221150010800_B7","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031221150010800_B8","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221150010800_B9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1463-1326.2006.00686.x","article-title":"Insulin-associated weight gain in diabetes\u2014causes, effects and coping strategies","volume":"9","author":"Russell-Jones","year":"2007","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/35\/11\/2198\/611410\/2198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/35\/11\/2198\/611410\/2198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T23:22:48Z","timestamp":1647127368000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/35\/11\/2198\/30688\/Remogliflozin-Etabonate-a-Selective-Inhibitor-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,13]]},"references-count":9,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,10,13]]},"published-print":{"date-parts":[[2012,11,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc12-0508","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,13]]}}}